{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:16:16Z","timestamp":1753892176908,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Hematological malignancies pose significant health challenges, with bortezomib emerging as a key therapeutic agent. However, its use is complicated by neurotoxicity, a side effect that urgently requires mitigation strategies. This study aims to provide a comprehensive bibliometric analysis to map the intellectual structure, historical trends, and emerging research fronts in the field of bortezomib-induced neurotoxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic search in the Web of Science Core Collection, capturing literature from 2002 to 2024. Articles written in English were selected for analysis. Bibliometric analysis was performed using VOSviewer, CiteSpace, and R 4.3.3 to visualize collaborations, keyword co-occurrences, and bibliographic coupling.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overview of this study reveals a rich tapestry of academic engagement encompassing 745 publications. The USA and China were the most productive countries, with Harvard University and the Dana-Farber Cancer Institute leading in institutional contributions. The New England Journal of Medicine stood out as the most influential journal. Prominent authors like Richardson Paul G. showcased the highest impact, with central research themes focusing on therapeutic approaches and peripheral neuropathy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This bibliometric analysis provides a detailed overview of the research landscape in bortezomib-induced neurotoxicity, identifying the USA and China as leading contributors and highlighting the central focus on therapeutic strategies and peripheral neuropathy management. These findings emphasize the need for global collaboration to develop effective mitigation strategies for neurotoxicity and improve patient outcomes. Insights from this study can guide future research efforts and inform clinical practices in managing bortezomib-related side effects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1584383","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:38:08Z","timestamp":1747201088000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global trends and collaborations in bortezomib-induced neurotoxicity research: a bibliometric analysis (2002\u20132024)"],"prefix":"10.3389","volume":"16","author":[{"given":"Pin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/08820538.2021.1922975","article-title":"Understanding the \u201cg-index\u201d and the \u201ce-index\u201d","volume":"36","author":"Ali","year":"2021","journal-title":"Semin. Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"n2116","DOI":"10.1136\/bmj.n2116","article-title":"Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART)","volume":"374","year":"2021","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/cncr.22921","article-title":"Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature","volume":"110","author":"Badros","year":"2007","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4081\/reumatismo.2020.1325","article-title":"Top 100 cited articles on ankylosing spondylitis","volume":"72","author":"Bagcier","year":"2021","journal-title":"Reumatismo"},{"key":"B6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3163\/1536-5050.103.4.013","article-title":"Bibliometrics basics","volume":"103","author":"Cooper","year":"2015","journal-title":"J. Med. Libr. Assoc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12883-022-02597-2","article-title":"Development and validation of the health education adherence scale for stroke patients: a cross-sectional study","volume":"22","author":"Ding","year":"2022","journal-title":"BMC Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ccell.2020.08.019","article-title":"Immunogenomic landscape of hematological malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1182\/blood.2019001751","article-title":"Lenalidomide in follicular lymphoma","volume":"135","author":"Flowers","year":"2020","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1053\/j.seminhematol.2018.05.007","article-title":"Diagnosis and classification of lymphoma: impact of technical advances","volume":"56","author":"Jaffe","year":"2019","journal-title":"Semin. Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7861\/clinmedicine.19-1-58","article-title":"Haematology: multiple myeloma","volume":"19","year":"2019","journal-title":"Clin. Med. (Lond)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/toxics3030294","article-title":"An overview of bortezomib-induced neurotoxicity","volume":"3","author":"Meregalli","year":"2015","journal-title":"Toxics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2174\/138920106779116919","article-title":"Thalidomide in multiple myeloma","volume":"7","author":"Moehler","year":"2006","journal-title":"Curr. Pharm. Biotechnol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.4103\/jfmpc.jfmpc_1613_23","article-title":"The h-Index: understanding its predictors, significance, and criticism","volume":"12","author":"Mondal","year":"2023","journal-title":"J. Fam. Med. Prim. Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40037-021-00695-4","article-title":"Bibliometrics: methods for studying academic publishing","volume":"11","author":"Ninkov","year":"2022","journal-title":"Perspect. Med. Educ."},{"key":"B23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","article-title":"From thalidomide to rational molecular glue design for targeted protein degradation","volume":"64","author":"Oleinikovas","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.30621\/jbachs.1018824","article-title":"Evaluation of the 100 most cited articles on behcet\u2019s disease: a bibliometric analysis","volume":"6","author":"\u00d6zduran","year":"2022","journal-title":"J. Basic Clin. Health Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/joim.13697","article-title":"Novel precision medicine approaches and treatment strategies in hematological malignancies","volume":"294","author":"Rosenquist","year":"2023","journal-title":"J. Intern Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"22799036221149840","DOI":"10.1177\/22799036221149840","article-title":"A new system of authorship best assessment","volume":"12","author":"Saba","year":"2023","journal-title":"J. Public Health Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"CD010816","DOI":"10.1002\/14651858.CD010816.pub2","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ijsu.2020.12.008","article-title":"Impact of the coronavirus (COVID-19) pandemic on scientific research and implications for clinical academic training \u2013 a review","volume":"86","author":"Sohrabi","year":"2021","journal-title":"Int. J. Surg."},{"key":"B32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11523-022-00945-3","article-title":"Selinexor-bortezomib-dexamethasone: a review in previously treated multiple myeloma","volume":"18","author":"Syed","year":"2023","journal-title":"Target Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of bortezomib","volume":"58","author":"Tan","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/14740338.2021.1991307","article-title":"Thalidomide: history, withdrawal, renaissance, and safety concerns","volume":"20","author":"Vargesson","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1111\/jns.12338","article-title":"Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24","author":"Velasco","year":"2019","journal-title":"J. Peripher Nerv. Syst."},{"key":"B37","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1097\/js9.0000000000001470","article-title":"Bibliometric analysis and global trends in uterus transplantation","volume":"110","author":"Wu","year":"2024","journal-title":"Int. J. Surg."},{"key":"B40","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/ijms22020888","article-title":"Pathological mechanisms of bortezomib-induced peripheral neuropathy","volume":"22","author":"Yamamoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1584383\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:38:10Z","timestamp":1747201090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1584383\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":42,"alternative-id":["10.3389\/fphar.2025.1584383"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1584383","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1584383"}}